Evidence Reference — Peyronie's Disease

Technical backup for every claim in Your Guide

AI Disclosure: This evidence reference was compiled by a coordinated team of AI research agents. Every entry traces to a specific published source identified by PMID. The evidence was independently verified by two AI reviewers using structured pair review. This is educational content — not medical advice.

How to use this document: When Your Guide makes a claim and cites (Author Year), find the matching entry here for the full study details — design, sample size, methodology, exact findings, and limitations.

---

§1 — Disease Foundation

§1.1 Mechanism and Epidemiology

Kadioglu 2011

PMID: 21233397 | Design: Retrospective | n: 1,001 | Journal: J Androl Key findings: Largest PD cohort study. 74% mild-moderate curvature (≤60°). Independent predictors of curvature severity: age (P=.013), deformity side (P=.007), ED (P<.0001), diabetes (P=.001). ED was MORE common in milder deformity groups — proposed explanation: less intercourse → less cumulative trauma → less severe curvature. DM patients: mean curvature 45.2° vs 30.2° without DM. Dorsal curvature associated with more severe deformity (tunica thicker dorsally). Left-sided curvature 3× more frequent than right. Limitations: Retrospective, single center, lacked obesity/smoking/testosterone data.

Paulis 2024

PMID: 38893650 | Design: Retrospective | n: 564 | Journal: Diagnostics Key findings: 88.4% significant anxiety (GAD-7 >9). 38.8% severe anxiety. 57.6% significant depression (PHQ-9 >9). 24.2% were ≤40 years. 35.6% chronic prostatitis. 35.6% plaque calcification. 88.2% had penile shortening (most common deformity). 16.1% multifocal plaque. Active phase documented at 22-26 months in 5 patients — pain absent but curvature still worsening. Only 29% recalled specific penile trauma. ED pre-existed PD in 56.4% of PD+ED cases. Younger patients had more pain; older patients had more ED. IIEF did NOT correlate with curvature severity (p=0.359), plaque volume (p=0.09), or disease duration (p=0.554). Limitations: 99.1% Caucasian, Italian single-center, specialist-seeking active-phase population only. Community rates likely differ. Referral bias elevates anxiety/depression rates.

§1.2 Disease Phases

ICSM 2024 (Chung 2026)

PMID: 41359447 | Design: Modified Delphi consensus | Journal: Sex Med Rev Key finding on phases: "There is no universally agreed-upon definition of the acute phase, and there is likely heterogeneity in the timeline for most patients." Active phase = progressive deformity (functional definition), NOT fixed months. Stable phase = curvature unchanged ≥3 months. Surgical eligibility = stable ≥6 months. Pain may persist in stable phase ("pain with erection may be present due to torque or stretch on the penile scar"). Pain resolution alone does NOT confirm stability. Also: IFN alpha-2B no longer commercially available. Traction: Conditional Recommendation (Moderate Quality of Evidence). SCT/PRP: Strong Recommendation against. CCH withdrawn outside USA.

§1.3 Natural History

Mulhall 2006 (abstract only)

PMID: 16697815 | Design: Observational | n: 246 Key findings: 48% worsen, 40% stable, 12% improve. Penile pain resolved in 89%. Length decreased.

Berookhim 2014 (abstract only)

PMID: 24053665 | Design: Observational | n: 176 Key findings: 67% stable, 21% worsen, 12% improve. Age ≤40 and ≤6 months → better prognosis.

Grasso 2007 (abstract only)

PMID: 17601314 | Design: Observational | n: 110 Key findings: <50yr: 68% worsened and required surgery. ≥50yr: 31.5%. Diabetes OR=6 for progression.

§1.4 Doppler Interpretation

Brian's Doppler (Lamb, March 19, 2026)

Penile arterial diameter: Normal. Maximum flow: Normal. Time to peak: Normal. Venous phase flow: Minimal (NORMAL — veins closing properly). Erection: 90%. Plaque: dorsal mid-to-distal shaft, 40° upward curvature. Calcification: NOT mentioned (absence of assessment, not confirmed absent).

§1.5 Volume-Loss Deformities

Margolin 2018

PMID: 30342867 | Design: Retrospective | n: 128 | Journal: Sex Med Key findings: 65% had volume-loss deformities (hourglass 23%, indentation 39%, distal tapering 13%). After controlling for curvature angle: axial instability OR 3.5 (P=.01), psychological distress OR 2.6 (P=.03), decreased sexual activity OR 2.7 (P=.02). Indentation: highest rates of instability (48%), distress (72%), decreased activity (62%).

§1.6 Psychological Impact

Punjani 2021

PMID: 33712403 | Design: Retrospective | n: 408 | Journal: J Sex Med Key findings: 27% clinically depressed (CES-D ≥16). Curvature degree NOT a predictor of depression on multivariable. Being partnered protective (OR 0.42, P<.01). Only total SEAR score significant on multivariable (OR 0.96, P<.001). Prior depression: OR 2.93.

Goldstein 2017

PMID: 28395998 | Design: Open-label phase 3 | n: 189 men + 30 partners | Journal: Sex Med Key findings: 36.3% curvature improvement. Female partner sexual dysfunction dropped 75% → 33.3%. BUT: correlation between curvature improvement and partner FSFI improvement was LOW and NOT significant — partner benefit appears driven by reduced bother/behavioral change, not curvature correction.

§1.7 Testosterone

Mulhall 2019

PMID: 31303573 | Design: Prospective database | n: 184 | Journal: J Sex Med Key findings: Total testosterone NOT associated with curvature magnitude (r=-0.01, P=0.95). Free testosterone NOT associated (r=-0.08, P=0.30). No association in multivariable model. Critiques Moreno study methodology.

---

§2 — Treatment Landscape

§2.1 Guidelines Comparison

Chierigo 2026 (Guideline of Guidelines)

PMID: 41795618 | Design: Guideline synthesis | Journal: BJU Int Key finding: Cross-society comparison of AUA/EAU/CUA/ISSM. Significant divergences on verapamil (AUA conditional, CUA recommends, EAU against), CCH (EAU strongest endorsement at Level 1b), HA (EAU/ICSM against outside trials). North American guidelines more permissive than EAU. ⊕ Correction: Chierigo rendered CUA's verapamil position as Level 2, Grade B. Primary source (Bella 2018) shows Level 3, Grade C. GoG overstated CUA's evidence grading.

Nehra 2015 (AUA Guideline)

PMID: 26066402 | Design: Systematic review, 303 articles | Journal: J Urol Key findings: Verapamil: "Conditional Recommendation, Grade C" — "the evidence for the use of intralesional verapamil is weak; clinicians should carefully consider whether use of this treatment is appropriate given the substantial uncertainty regarding its efficacy and the availability of other treatments that are clearly more effective." CCH: "Moderate Recommendation, Grade B" — "a modest difference of 7.7°." ESWT: "overall utility of ESWT in the management of PD is low." Traction: "insufficient evidence" (Other Treatments table). IFN: "most appropriate for the patient with stable disease."

Bella 2018 (CUA Guideline)

PMID: 29792593 | Design: Expert consensus, literature cutoff 6/30/2017 | Journal: CUAJ Key findings: Only major society that RECOMMENDS intralesional verapamil (Level 3, Grade C) — "widely used in Canada with more than two decades of experience." Recommends traction (Level 4, Grade C). HA: "too early to make any recommendations." ⊕ Internal inconsistency: cites Favilla 2017 (ref 52) for HA evidence but does NOT reconcile the zero verapamil finding with ongoing verapamil recommendation. Plication perception gap (Hudak): 84% no measurable SPL decrease, 78% perceived reduction.

§2.2 Oral Therapies

Pentoxifylline — Safarinejad 2010 (abstract only)

PMID: 19863517 | Design: RCT | n: 228 Key findings: Progression 11% with PTX vs 42% placebo (P=.01). Only oral agent with positive RCT data for curvature progression prevention.

PDE5 Inhibitors — Durukan 2024

PMID: 38228873 | Design: Retrospective cohort | n: 133 | Journal: Int J Impot Res Key findings: PDE5i daily: NO significant curvature prevention (P=.08). Pain duration shortened: 9.1 vs 12.2 months (P=.04, univariable Wilcoxon only — NOT adjusted for confounders). Curvature measured by self-photography (not pharmacological erection + goniometer).

Mayo Clinic Oral Protocol (Ziegelmann 2020)

Pentoxifylline 400mg t.i.d. + L-citrulline 750mg b.i.d. + tadalafil 5mg daily (if concurrent ED). Standard Mayo PD oral protocol.

§2.3 Practice Patterns

Brant 2023

PMID: 36815582 | Design: Cross-sectional survey | n: 145 US urologists (from 12,018 surveyed, ~1.2% response rate) | Journal: Andrology Key findings: 21% currently use AUA-discouraged treatments. Only 60% perform in-office curvature assessment. 81% have NO fellowship training in andrology/sexual medicine. Fellowship-trained vs non-fellowship: CCH 89% vs 54% (P<.001), traction 78% vs 47% (P=.004), in-office assessment 85% vs 54% (P=.003), duplex US 70% vs 24% (P<.001). 41% of CCH users use it off-label. Even among those claiming to follow AUA guidelines, 21% still use discouraged treatments. Younger urologists (<20 years) more evidence-based across all measures. Self-selection bias: 21% AUA-violation figure likely underestimates real-world non-adherence.

---

§3A — CCH (Xiaflex)

Zhang 2022 (Meta-analysis)

PMID: 36278151 | Design: Meta-analysis, 11 prospective studies | n: 1,480 | Journal: Front Pharmacol Key findings: 35% pooled curvature improvement (I²=0.00% — zero heterogeneity). 41% PD bother improvement. 93% TRAEs (mostly mild). Modified protocols may retain same effectiveness. No publication bias for curvature outcome.

Gelbard 2013 — IMPRESS I+II (abstract only for primary, cited in multiple sources)

PMID: 23376148 | Design: Double-blind RCT | n: 832 Key findings: CCH -17° (-34%) vs placebo -9.3° (-18%), P<0.0001. AUA characterizes the net difference as "a modest difference of 7.7°." 46% met composite responder criteria (≥20% curvature improvement + >1-point PDQ bother reduction). 3 corporal ruptures (0.36%). 84.2% of CCH patients had ≥1 adverse event vs 36.3% placebo. Phase IIb showed NO significant benefit in the non-modeling arm — modeling contributes substantially to outcomes. Exclusions: hourglass, ED, ventral curvature, significant calcification — pre-selected favorable population.

Flores 2022

PMID: 36127227 | Design: Retrospective | n: 114 | Journal: J Sex Med Key findings: 44% improved, 39% no change, 17% worsened (improvement threshold has internal inconsistency: abstract says ≥20%, Table 2 footnote says ≥25%). Among responders: mean -22° (-41%). Baseline curvature THE predictor: OR 1.33 per 10° (P=.02). By baseline: ≤30°: 29%, 31-59°: 43%, ≥60°: 60%. Calcification NS (OR 0.92, P=.88 — likely underpowered, ~15% calcified). Cycle-2 decision principle supported. Traction 2-6h/day.

Lumbiganon 2025

PMID: 40223660 | Design: Retrospective 7-year | n: 292 | Journal: J Sex Med Key findings: 70.89% compliance. Compliant: 44.44% curvature reduction vs non-compliant 33.33% (P=.034). Dorsal best response (50.09%), ventral worst (33.57%). 4 suspected penile fractures (1.4%) during intensive 3×/day modeling. Non-compliance: AEs 15.1%, early satisfaction 14.1%, unknown 45.4%. Limitations: Single-center tertiary referral. 7-year retrospective. Modeling intensity not standardized across patients.

Cao 2022 (RCT Meta-analysis)

PMID: 35252236 | Design: Meta-analysis, 5 RCTs | n: 1,227 | Journal: Front Med Key findings: CCH significant for curvature (P<0.001) and bother (P<0.001). Pain: NO difference vs placebo (P=0.39). TAE OR 12.86 (P<0.001). No industry funding. Limitations: Most included RCTs are Endo-sponsored. Only 5 RCTs available for inclusion.

Capece 2018

PMID: 29733116 | Design: Prospective multicenter | n: 135 | Journal: Andrology Key findings: Ralph's shortened protocol: 3 injections of 0.9mg at 4-week intervals + daily modeling/stretching/vacuum 2×/day. 94.8% improved (ANY decrease — loose definition). Mean -19.1° (-42.9%). 0% Clavien III complications. 92.6% ecchymosis. Higher dose (0.9mg vs IMPRESS 0.58mg) explains higher bruising rate.

Alom 2019 (abstract only)

PMID: 30956106 | Design: Retrospective comparative | n: 113 Key findings: CCH + RestoreX: -33.8° vs CCH alone -20.3° vs CCH + conventional traction -19.2°. RestoreX patients 6.9× more likely to achieve ≥20° improvement. Abstract-only — cited via ESSM position statement (García-Gómez 2021).

Cocci 2020 (abstract only — paywall)

PMID: 32342279 | Design: Prospective single-arm | n: 74 | Journal: Clin Drug Invest Key findings: Single CCH injection in acute phase: -19.3° (P<0.0001). Baseline curvature and time since onset predicted improvement. Off-label for acute phase. Uncontrolled.

Trost 2021

PMID: 33684795 | Design: Claims database, PS-matched | n: 620/cohort | Journal: Sex Med Key findings: CCH fewer post-procedural complications (18.4% vs surgery 25.3%, P=.003). Less ED (44.8% vs 65.0%). Less opioid use (38.9% vs 93.3%). Corporal rupture: CCH 1.8% vs surgery 0.8% (NS). Limitations: Claims-based — no clinical curvature measurements. Endo Pharmaceuticals-funded.

Trost 2023

PMID: 35013566 | Design: Claims database | n: 1,227+620 | Journal: Int J Impot Res Key findings: CCH first → 4.6% subsequent surgery (12 months) vs surgery first → 10.3% (P<0.0001). Difference narrowed at 24 months (8.7% vs 10.7%, NS). Prior CCH does NOT increase surgical complications. Limitations: Claims-based. Endo Pharmaceuticals-funded. Lead-time bias acknowledged.

Calcification Evidence — Genuinely Unsettled

Wymer 2018 (abstract only)

PMID: 29908867 | Design: Retrospective | n: 115 Key findings: Noncalcified patients OR 2.50 for CCH improvement. 67% noncalcified vs 41% calcified improved.

Masterson 2023 (abstract only)

PMID: 36272924 | Design: Retrospective | n: 47 Key findings: Calcified patients CAN improve with CCH (-17.5°). Contradicts Wymer — needs reconciliation.

Calcification evidence status (updated with Cahill 2025): Three data points — one positive (Wymer, n=115), one contradictory (Masterson, n=47), one NS in the largest series (Cahill, n=826, P=.37). Weight of evidence now favors: calcification is NOT a reliable predictor of CCH failure. Partial calcification is not a contraindication. ICSM 2024: "calcification does not signify chronic disease — may represent a different genetic subtype." See consolidated Cahill 2025 entry below.

Walton 2022

PMID: 35461065 | Design: Claims database | n: 89,205 | Journal: Sex Med Key findings: CCH $6,940-8,895/cycle, median 2 cycles = ~$15-18K total. OOP <$300/cycle. Surgery $1,856-3,631. Verapamil ~$60/year.

Tsambarlis 2019

Cited via: Ziegelmann 2020 (secondary source — primary paper: Tsambarlis et al. 2019, Int J Impot Res, ref 87 in Ziegelmann) Design: Post-approval | n: 45 Key finding: Real-world mean curvature reduction 5.4° — vs IMPRESS 17°. Real-world efficacy gap.

Cahill 2025 — LARGEST PROSPECTIVE CCH PREDICTOR STUDY

PMID: 40814201 | Design: Prospective sequential database | n: 826 | Journal: J Sex Med 2025 Key findings:

• Median curvature improvement: 27.5° (Most Recent) / 32.5° (Completed 8 or Satisfied). ⚠️ Trost-protocol specific — uses aggressive in-office modeling, 0.9mg dose, wrapping, and RestoreX in 98% of patients. NOT standard IMPRESS protocol. Not generalizable to community CCH practice.
• RestoreX: Associated with 19.5° greater improvement on multivariate (P=.02). The strongest predictor across all models. ⚠️ Confound: By 2019+, 98% used RestoreX → insufficient power in non-use arm → cannot cleanly separate RestoreX benefit from concurrent protocol changes.
• Hourglass/indentation: Moderate/severe → 3-10° MORE improvement than none/mild (P<.0001 univariate; multivariate P=.02). Counterintuitive: More severe indentation predicts BETTER CCH response. Contradicts prior assumption that hourglass precludes CCH.
• Calcification: NS (P=.37) — not a significant predictor. See calcification evidence status above (Wymer/Masterson/Cahill synthesis).
• Active phase: NS (P=.48) — CCH may safely and effectively be used in active phase.
• Disease duration: NS (P=.37) — duration does not predict outcomes.
• Lateral curvature: -11.2° worse outcomes (multivariate P<.001). Dorsal/dorsolateral: best response.
• Motivation/bother: Higher PDQ bother and psych/physical scores correlated with better outcomes. Decreased self-reported motivation: 7° worse.
• Controlled fracture: Popping sensation +4.4° (P<.01), rapid detumescence +4.6° (P<.01) — from aggressive in-office modeling.
• IIEF: Zero change post-CCH across all domains (consistent with Osmonov: IIEF not validated for PD).
• 44% completed 4 series or stopped satisfied — consistent with Flores 44%. Limitations: Single-center (Trost's clinic, Utah). Protocol evolved substantially over 10 years. RestoreX confound. ⚠️ Triple COI: Trost is inventor of RestoreX, part-owner of PathRight Medical, and received investigator-initiated grants from Endo Pharmaceuticals (CCH manufacturer). Also Editor-in-Chief of J Sex Med (the publishing journal). Declared; editorial process delegated.

---

§3B — Hyaluronic Acid

Favilla 2017

PMID: 28718527 | Design: Double-blind RCT | n: 140 (69V/63HA) | Journal: Andrology Key findings: Verapamil: 0.00° ± 0.00 curvature change. HA: -4.60° (P<0.001). Both reduced plaque (-1.36mm vs -1.80mm, NS). Both improved IIEF (NS between groups). HA PGI-I: 3.13 vs V 3.53 (P<0.05). Zero AEs. Acute phase, 11 Italian centers, weekly × 12 weeks.

Abdel Fattah 2024

PMID: 39355797 | Design: Double-blind RCT | n: 42 | Journal: Arab J Urol Key findings: HA -9.4° vs V -5.4° (P=0.038). HA better for plaque size (P<0.001 vs NS for V). Acute phase. Small sample.

Cilio 2024

PMID: 38305689 | Design: Retrospective | n: 62 | Journal: Asian J Androl Key findings: Only HA study in stable phase. 3 injections at 2-week intervals + vacuum + stretching + modeling. 87.1% responded. Mean -12.4° (23%). Calcification NOT predictive (P=0.847). Zero significant AEs. Cannot separate HA effect from mechanical adjunct.

Guideline status (2026): EAU recommends AGAINST outside clinical trials (Level 3c, Strong). ICSM 2024: "does not support." Approved only in Italy.

---

§3C — Traction

Ziegelmann 2019 RestoreX RCT (abstract; full data in Ziegelmann 2020 review)

PMID: 30916626 | Design: RCT | n: 100 Key findings: RestoreX 30-90 min/day × 3 months. Curvature: -11.7° vs +1.3° control (ITT). SPL: +1.5cm vs 0cm. >75% curvature improvement; ~95% SPL improvement. First study showing benefit at <3 hours daily. Note: Ziegelmann is both the RCT author and the 2020 review author (self-citation).

ICSM 2024 (Chung 2026) Rec #17: "Penile traction therapy can reduce penile deformity as monotherapy or may be offered as part of a multimodal therapy approach." Conditional Recommendation, Moderate Quality of Evidence.

---

§3D — Verapamil

Favilla 2017 (see §3B above)

Verapamil arm: 0.00° ± 0.00. Zero curvature change in the only double-blind RCT.

Shirazi 2009 (abstract)

Verapamil -2.1° vs placebo -2.2°. NS. n=80.

Paulis 2012

PMID: 21950543 | Design: Retrospective, uncontrolled | n: 151 Key findings: Best combo (verapamil + iontophoresis + vitamin E + propolis): -14°. Injection-only verapamil: -2.7° to -4.5°. Active ingredient may be propolis (NF-κB inhibitor), not verapamil.

Levine 2002

PMID: 12454681 | Design: Uncontrolled | n: 156 Key findings: 60% "objectively improved." No placebo. 30.4 months follow-up. The foundational verapamil paper. Stub — limited content.

Pattern: Uncontrolled studies positive. Every controlled trial negative.

---

§4 — Decision Factors + Surgical Evidence

Osmonov 2022 (ESSM Position Statement)

PMID: 34823053 | Design: Systematic review, 131 studies | Journal: Sex Med Key findings: 18 position statements. Plication: straightening 48-100%, satisfaction 58-96%. Grafting: recurrence 50-78% long-term. TachoSil: 83-95% straightening, 91.5% satisfaction, shortest operative time. Glans hypoesthesia: plication up to 53%, grafting up to 39% — mostly transient. Statement #14: post-CCH surgery feasible without increased complications (harder within 3 months). >70% of patients report penile shortening BEFORE surgery. IIEF not validated for PD — all surgical ED outcome data uses a non-validated instrument. Limitations: Literature 2009-2019 only. Misses RestoreX RCT and all post-2019 data.

Garaffa 2024 (abstract only)

PMID: 38388784 | n: 91 Key finding: Plication does NOT cause additional length loss (P=0.466). "The perceived length loss has already occurred prior to surgery." Perception gap (Hudak): 84% no measurable loss, 78% perceived loss.

Reed-Maldonado 2018

PMID: 29644164 | Design: Retrospective | n: 17 with follow-up (36 total) | Journal: Transl Androl Urol Key findings: Extra-tunical grafting (ETG) for hourglass/indentation. All 17 reported satisfactory resolution — but 13/17 had concurrent plication. 94.1% satisfied, 11.8% mild hypoesthesia, zero ED worsening. ETG does NOT violate tunica albuginea or dissect NVB. Also used for post-CCH corporeal herniation. Graft initially more prominent in flaccid state, normalizes by 6 months. Limitations: n=17, retrospective, single surgeon, no validated questionnaire, plication confound in 76% of cohort. Promising preliminary evidence, not established efficacy.

---

§5 — Red/Green Flags + Practice Gap Evidence

Key practice gaps documented:

1. Verapamil without evidence: Only double-blind RCT shows zero benefit. 43% of urologists historically used it; declining but still prevalent.
2. Assessment gaps: Only 60% perform in-office curvature assessment. Volume-loss deformities (65% prevalence) often unassessed.
3. Guideline-evidence disconnect: CUA recommends verapamil while citing Favilla 2017 (which shows zero benefit) in the same document.
4. Evidence-practice lag: Favilla 2017 showed zero verapamil benefit — still widely prescribed 8+ years later.
5. Training gap: 81% of PD-treating urologists have no andrology fellowship. Every evidence-based practice is significantly more common in fellowship-trained physicians.
6. Non-standard protocols: No published protocol uses 3-month verapamil intervals. Brian's treatment had no evidence base.

Practice Gap Report — Peyronie's Disease

What Your Doctor May Have Missed (and How We Know)

Document C | BringThisIn.com

---

What this document is: A research-backed analysis of common gaps in PD care, drawn from published physician surveys and confirmed by a real patient's experience. Every claim cites a specific study with author, year, sample size, and source type.

For the underlying evidence behind each gap, see the Evidence Reference (Document B). For how this analysis was conducted, see our Process & Transparency page.

What this document is NOT: An attack on any individual doctor. Most PD care gaps are systemic — driven by training patterns, practice economics, and evidence-practice lag. Your doctor may be doing their best within a system that doesn't support thorough PD care.

---

Gap 1: Volume-Loss Deformities Go Unassessed

What the evidence says: 65% of PD patients have volume-loss deformities — hourglass (23%), unilateral indentation (39%), and/or distal tapering (13%). These are independently associated with axial instability (OR 3.5), psychological distress (OR 2.6), and decreased sexual activity (OR 2.7) — even after controlling for curvature degree. (Margolin 2018, n=128, retrospective case series) [Chart review]

Brian's experience: "It's distinctly thinner on top 1/3 with a clear restriction where the problem section is." His urologist did not assess for volume-loss deformities. The Doppler report mentions plaque location and curvature only — no indentation, hourglass, or axial instability assessment.

What to ask your doctor: "Can you assess specifically for hourglass deformity, indentation, and distal tapering? And test for axial instability? I'm noticing [describe what you observe]."

Why this matters: Volume-loss deformities affect treatment selection. Extra-tunical grafting (ETG) may be appropriate for significant indentation. Standard CCH or plication protocols don't address volume loss. If your doctor doesn't look for it, your treatment plan may miss a significant component of your condition.

---

Gap 2: Non-Standard Treatment Protocols

What the evidence says: 21% of US urologists currently use treatments the AUA explicitly discourages — even among those who say they follow AUA guidelines. (Brant 2023, n=145, physician survey, 1.2% response rate) [Survey — self-report bias; non-respondent skew likely underestimates gap]

Published verapamil injection protocols use biweekly to monthly intervals (Levine 1994: biweekly × 6 months; Favilla 2017: weekly × 12 weeks). No published protocol uses intervals longer than monthly.

Brian's experience: Received verapamil injections at 3-month intervals — a schedule with zero published support. No modeling protocol prescribed. No traction device recommended.

What to ask your doctor: "Published verapamil protocols use biweekly to monthly intervals. What's the reasoning for a different schedule? And what mechanical adjunct — modeling or traction — is part of the protocol?"

Why this matters: The only double-blind RCT of intralesional verapamil (Favilla 2017, n=140) showed zero curvature change. Even the weak positive uncontrolled data used much higher injection frequency than 3-month intervals. A non-standard protocol based on non-evidence-based treatment compounds the gap.

---

Gap 3: No Treatment Options Discussion

What the evidence says: Only 60% of urologists perform thorough pre-treatment assessment including in-office curvature measurement. Fellowship-trained sexual medicine specialists perform thorough evaluations 85% of the time vs 54% for non-fellowship-trained (P=.003). (Brant 2023, n=145) [Survey]

81% of urologists treating PD have no fellowship training in andrology or sexual medicine. (Brant 2023) [Survey]

Brian's experience: No treatment alternatives were discussed. No mention of CCH (Xiaflex), hyaluronic acid, traction therapy, or surgical options. "Never talked to me about the options. No meeting with him ever took more than 3 minutes."

What to ask your doctor: "What are my treatment options? I'd like to understand the evidence for each — CCH, hyaluronic acid, traction, and surgery — and which one fits my specific situation."

Why this matters: Informed consent requires understanding alternatives. A 3-minute encounter cannot provide meaningful informed consent for a condition with multiple evidence-graded treatment options.

---

Gap 4: Refusing Outside Imaging

What the evidence says: This is a documented systemic pattern across medical specialties — not specific to PD. Outside imaging refusal functions as patient lock-in (billing capture, information asymmetry, scheduling control). (Systemic analysis — no PD-specific survey data) [Expert analysis]

Brian's experience: Another urologist could perform the Doppler in 2 weeks. Brian's urologist refused to accept it, requiring a 3-month wait for his own Doppler. This added 3 months to an already-delayed timeline during which the disease was actively progressing.

What to ask your doctor: "If I've had imaging done elsewhere, will you review and accept it? If not, why not — and how soon can you schedule your own?"

Why this matters: Every month of delay during active-phase PD is a month of potential progression. A 3-month wait for a Doppler that takes minutes to perform delays treatment decisions during the most critical treatment window.

---

Gap 5: Verbal/Written Report Discrepancy

What the evidence says: No specific survey data on verbal vs written discrepancies in PD care. However, verbal clinical communication often diverges from formal documentation — this is a recognized quality concern across all medical specialties.

Brian's experience: His urologist verbally told him there was "some reduced blood flow in some areas." The written Doppler report states all vascular parameters are Normal — arterial diameter, maximum flow, time to peak all normal, venous phase flow minimal (which is the desired finding). The verbal characterization doesn't match the written record.

What to ask your doctor: "Can you walk me through exactly what the Doppler report shows? I want to make sure I understand the written findings, not just the verbal summary."

Why this matters: Treatment decisions should be based on documented findings, not verbal impressions. If something the doctor says doesn't match the report, ask for clarification — one of them is wrong.

---

Gap 6: Evidence-Practice Lag

What the evidence says: The time for landmark clinical evidence to change clinical practice is documented as substantial across multiple medical specialties (Balas & Boren, Yearbook of Medical Informatics 2000; Morris et al., J R Soc Med 2011). For PD specifically: Favilla 2017 demonstrated zero verapamil curvature benefit in a double-blind RCT — yet verapamil remains widely prescribed in 2025. Sullivan 2015 (n=639) found vitamin E was the preferred initial management for 70% of US urologists, despite no evidence supporting its efficacy. (Sullivan 2015, n=639; Brant 2023, n=145) [Survey]

Brian's experience: Received verapamil in 2026 — 9 years after the definitive negative trial. The evidence against verapamil curvature efficacy was available since 2017. His urologist's practice pattern reflects the evidence base of ~2010, not 2025.

What to ask your doctor: "What's the most recent evidence you're relying on for this treatment recommendation? I've seen the Favilla 2017 double-blind RCT — how does that factor into your assessment?"

Why this matters: If your doctor's answer references studies from before 2015, or if they're unfamiliar with Favilla 2017 or the IMPRESS trials, they may not be current on PD evidence. This isn't a test — it's a calibration of whether the conversation is happening on the same evidence base.

---

Gap 7: Informed Consent in 3-Minute Encounters

What the evidence says: Meaningful informed consent requires understanding the diagnosis, the proposed treatment, the alternatives, the evidence for and against each, and the risks. For a condition with PD's complexity — multiple treatment options, phase-dependent selection, evidence-graded guidelines with cross-society disagreements — this is structurally impossible in a 3-minute encounter. (W2 analysis; supported by informed consent literature) [Expert analysis]

Brian's experience: "No meeting with him ever took more than 3 minutes." The encounter was too short to provide informed consent by any standard.

What to ask your doctor: This isn't a question for your doctor — it's a signal for you. If your PD encounter takes less than 10 minutes and doesn't include a discussion of alternatives, you may not be receiving care that allows meaningful informed consent. Consider seeking a second opinion from a fellowship-trained sexual medicine specialist.

---

Gap 8: No Mechanical Adjunct With Injectables

What the evidence says: Across multiple CCH studies, mechanical adjunct (modeling, traction) appears to be a necessary component for curvature correction. The IMPRESS Phase IIb trial showed no difference between CCH and placebo in the NON-MODELING arms. Studies with intensive multimodal mechanical adjunct (Capece 2018, n=135) report response rates higher than studies with standard modeling alone (IMPRESS Phase III, 46% composite responder). Note: these are cross-study comparisons with different cohorts and outcome definitions — not a head-to-head trial. (Multiple studies — see Evidence Reference §3.1) [Multiple RCTs + case series]

Brian's experience: Received verapamil injection with no modeling protocol, no traction device recommendation, no stretching instructions. "Never talked to me about" mechanical adjuncts.

What to ask your doctor: "What mechanical adjunct — modeling, traction, or vacuum device — do you prescribe with the injection? How often should I be doing it at home between visits?"

Why this matters: An injectable without mechanical adjunct may be missing the mechanism that produces curvature correction. If your doctor prescribes an injection without specifying a modeling/traction protocol, ask what the evidence says about mechanical adjuncts for that treatment.

---

How common are these gaps?

Gap	How we know	Estimated prevalence
Volume-loss unassessed	Margolin 2018 (n=128)	65% of patients have it; assessment rate unknown
Non-standard protocols	Brant 2023 (n=145)	21% use AUA-discouraged treatments
No options discussion	Brant 2023 (n=145)	40% don't do thorough pre-treatment assessment
No fellowship training	Brant 2023 (n=145)	81% treating PD have no andrology fellowship
Evidence-practice lag	Sullivan 2015 (n=639)	70% still preferred vitamin E (no evidence)
Informed consent gaps	Expert analysis	Structural in short encounters
No mechanical adjunct	Expert analysis from evidence pattern	Unknown; not surveyed

Geographic/practice caveat: Most survey data is US-centric and skewed toward academic medical centers. Community urology practices (like Brian's) may have different gap profiles. Survey response rates are low (Brant 2023: 1.2%), meaning non-responding urologists — who may be less evidence-aware — are underrepresented.

---

---

Where to go from here

If multiple gaps in this document match your own experience, that's the system — not you failing alone. Three concrete next steps:

1. Bring this document to a fellowship-trained sexual medicine specialist. Only 19% of urologists treating PD are fellowship-trained, but they're significantly more likely to engage on each of these gaps (Brant 2023: P<.005 for every evidence-based practice measured).
2. Review Your Guide (Document A) for treatment-specific questions tied to your situation.
3. If you can't access fellowship-trained care locally, document each gap that applies to your case for the next conversation with any provider. Knowing the gaps is the first step. Acting on them is the next.

---

This document was researched by a team of AI research agents under human direction. Every factual claim cites a specific published source. The evidence was independently verified by two AI reviewers using structured pair review with documented pushback. This is educational content — not medical advice. Always discuss treatment decisions with your healthcare provider.

Brian's Story

Throughout my life I have had terrible experiences with doctors. When I was first diagnosed with diabetes, my doctor never followed up with me on any actual blood sugar numbers. I noticed they were high, and I pushed for changes in my medicine — and he just accepted whatever I asked for. I switched doctors, and it was the same story all over. I researched doctors near me and found one that I liked. He had availability for new patients, but he worked in the same practice as my current doctor. I requested to switch but was denied that opportunity because it might "hurt my original doctor's feelings."

Time and time again I felt like I was dealing with people that were more interested in going to the country club and hanging out with their friends than actually taking care of me.

Even worse, it wasn't just me. When my daughter was a toddler, she had a regular issue where her elbow would make a popping noise and she would be in terrible pain for a few hours. We went to see a specialist, and while we waited the nurse whispered in our ear that she thinks it's probably just a case of nursemaid's elbow, and it will likely resolve on its own as she gets older.

Then the doctor came in. My daughter was on Medicaid at the time — I was an elementary school teacher and due to our income my daughters qualified for that. The doctor walked in. He didn't ask questions. He didn't take an x-ray. He didn't inspect her elbow. He immediately said, "I have been writing books and studying this condition for several years..." He went on to diagnose my daughter with some rare bone disorder and said we would need to put her in a cast for one year, but not to worry because he is the country's leading expert on this issue.

I told him we would be leaving. We got a second opinion, and it was in fact nursemaid's elbow. The nerve on the elbow would sometimes pop out of place, and there was a simple wrist movement that could pop it back in. She grew out of it.

I could go on, but let me focus on the most immediate experience.

---

I recently, in the last year, suffered an injury that led to a diagnosis of Peyronie's disease — a condition that affects the penis. At first I was confused. I thought maybe I had an infection, but then the pain became unbearable. As it got worse I went to a specialist. The specialist had me meet his nurse first, who scheduled a meeting with him — three months out.

I finally met with him. He spoke to me for all of two minutes and scheduled a Doppler ultrasound. He said he anticipated we would need to use an injection to fix the issue, but he needed the Doppler first. However, they couldn't schedule the Doppler for three months. I found another location able to do the same Doppler two weeks later, but the doctor's office told me he refuses to use any Doppler performed by any other office. I would have to wait.

Sadly, I did. My condition worsened — the pain died back but the deformity became significantly worse over that time period. I finally got the Doppler. Again, it was all of two minutes with the doctor.

Two weeks later I went back for the injection, and he said, "In three months we will see how the disease has progressed and do another shot if needed."

I tried to set up the next appointment but was told it would be difficult to schedule the staff needed, and to put a tentative date three months out. They'd let me know if they could make it work. I haven't heard back about it yet. As the weeks passed, there was no improvement.

---

At the same time as all of this was happening, I had changed careers. A decade earlier I had switched from elementary education to running an online retail operation. And eight months before this I switched to focus on AI, as I believe this is one of the most incredible moments in human history.

I had developed a system — a harness — that takes multiple AI agents and teaches them how to think more critically, how to push back on each other's conclusions, how to annotate their own uncertainty, and how to work together as a team. I then built the infrastructure for these agents to communicate and collaborate.

My brother works at MUSC, and he called me to ask about integrating AI into some of what his team was doing. I couldn't explain it all very well, but I said I could do it myself. So I started putting my AI team to the task of analyzing diseases for a WHO cancer genomics consortium wiki. There wasn't any money in it, but it was rewarding — and I learned a tremendous amount about harnessing a multi-agent AI team to find, sort through, and verify tens of thousands of research articles.

So here I was: no money, no profits, the last eight months of my life spent learning how to harness AI, my personal body breaking in ways that were terrifying, and no improvements to show for it.

And so I pointed my AI team at my own disease.

---

What I found was upsetting.

The injection I'd been given — verapamil — had no controlled studies showing it improves curvature in Peyronie's disease. The only double-blind randomized controlled trial (Favilla 2017, n=140) showed exactly zero curvature change: 0.00° ± 0.00 in the verapamil arm. There were a few uncontrolled studies showing marginal improvement, but every controlled trial was negative.

Then the second major discovery: in every single one of those studies, the protocol used a series of six or more injections at biweekly or monthly intervals. No published study has ever used a three-month interval. My team searched extensively — there is no evidence base for the schedule I was on.

There is also an FDA-approved injection specifically indicated for Peyronie's disease — collagenase clostridium histolyticum (Xiaflex) — supported by two large double-blind RCTs with over 800 patients (Gelbard 2013). It was never mentioned to me. Not once, in months of visits.

That is where I am right now. I am working to get a second opinion, but my insurance only includes two urologist locations — so this is still a work in progress. I plan to update here as I get it handled.

---

That experience led me to this website. I thought: this is extremely useful for me. I already have the harness and AI agents collaborating on diseases — I could build a website and ask other people if they want the AI teams to put together something similar for their condition too. Maybe no one does. I honestly don't know. But I know I am personally really glad I had the AI team at my disposal.

If you're dealing with something similar — a condition where you feel unheard, undertreated, or unsure whether your doctor's approach matches the evidence — share your situation. We'll see if we can do for you what I did for myself.

To be continued — second opinion scheduled.

---

Sources cited in this story

• Favilla 2017 — double-blind RCT, n=140, verapamil 0.00° ± 0.00 curvature change. PMID: 28718527
• Gelbard 2013 (IMPRESS) — CCH phase III RCTs, n=832. PMID: 23376148
• Full evidence for all claims: Evidence Reference →